4.3 Article

Medications for Weight Reduction

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ecl.2008.08.004

关键词

Sympathomimetic drugs; Lipase inhibitor; Cannabinoid receptor antagonists; Glucagon-like peptide analogues

向作者/读者索取更多资源

Only two drugs are currently approved for long-term use in the treatment of obesity and four others for short-term use. Evaluating the risk-benefit profile is an essential first step. For individuals who have a low body mass index for whom the risk is small, the risk profile must make the drug acceptable for almost everyone. For higher-risk patients, such as those planning intestinal bypass or who have sleep apnea, a wider range of drugs may be considered. Obesity is a chronic disease that has many causes. Treatment is aimed at palliation-that is, producing and maintaining weight loss. Regardless of the primary site of action, the net effect must be a reduction in food intake or increase in energy expenditure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据